<DOC>
	<DOCNO>NCT02464397</DOCNO>
	<brief_summary>The purpose study compare vascular healing stented segment deployment titanium-nitride-oxide coat cobalt-chromium OPTIMAX™ bio-active stent ( BAS ) SYNERGY™ everolimus-eluting stent ( EES ) patient acute coronary syndrome require percutaneous coronary intervention . Patients treat BAS treat DAPT least 4 week procedure follow aspirin alone , patient EES group treat DAPT , least 6 month post procedure . In addition , study collect initial information safety effectiveness BAS comparison EES group 30 day , 6 month , 12 month .</brief_summary>
	<brief_title>Comparison Strut Coverage With OPTIMAX Versus SYNERGY Stents</brief_title>
	<detailed_description>OPTIMAX-OCT prospective , randomize ( 1:1 ) , study conduct 2-3 site ( Finland , Belgium ) evaluate OPTIMAX-BAS vascular healing pattern thrombus formation OCT one ( Study A ) six ( Study B ) month stent implantation comparison SYNERGY-EES . Patients receive BAS receive dual antiplatelet treatment ( DAPT ) least four week follow aspirin , patient implant EES , receive DAPT least 6 month follow aspirin . Patients randomize study A B follow : Study A : OPTIMAX-BAS ( n=25 ) versus SYNERGY-EES ( n=25 ) . First 50 patient randomize study A. OCT 1 month follow . Study B : OPTIMAX-BAS ( n=30 ) versus SYNERGY-EES ( n=30 ) Following 60 patient randomize study B. OCT 6 month follow . Randomization use time recruitment seal envelope . Patients randomize 1:1 fashion . First 50 patient randomize study A following 60 patient study B . Patients study A OCT follow 1 month index procedure patient study B OCT 6 month . OCT analyse perform blind patient 's characteristic well type stent use . Two ( 2-3 ) investigational site : - Cardiovascular Center Aalst , Aalst , Belgium - Heart Center , Satakunta Central Hospital , Pori , Finland</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tryptophan</mesh_term>
	<criteria>1 . Age &gt; 18 &lt; 80 year 2 . STEMI NSTEMI ( assume investigator type 1 myocardial infarction , accord universal definition MI ; EHJ 2007 ; 28 ( 20 ) :252538 ) ; unstable angina ( clinical symptom chest pain , ecg suggestive reversible ischemia ) 3 . Patient willing comply specify followup evaluation 4 . Patient legally authorize representative inform nature study , agree provision provide write informed consent , approve appropriate Medical Ethics committee Institutional Review Board . 5 . Single de novo nonstented restenosis lesion 6 . Patients twovessel disease may undergo successful treatment nontarget vessel approve device include index procedure must prior index target vessel treatment . 7 . Target lesion ( maximum 20 mm length visual estimation ) cover single stent maximum 23mm length . 8 . Reference vessel diameter must &gt; 2.5mm &lt; 4.0mm visual estimate . 9 . The vessel diameter measure predilation procedure intracoronary nitroglycerin vasospasm suspect . 10 . Target lesion &gt; 50 % &lt; 100 % stenosed visual estimate . 1 . Impaired renal function ( serum creatinine &gt; 177micromol/l ) dialysis 2 . Platelet count &lt; 10 e5 cells/mm3 3 . Patient history bleed diathesis coagulopathy patient antiplatelet and/or anticoagulation therapy contraindicate . 4 . Patient receive organ transplant wait list organ transplant . 5 . Patient known hypersensitivity contraindication aspirin , heparin/bivalirudin , clopidogrel/prasugrel/ticagrelol , cobalt chromium alloy , contrast agent adequately premedicated . 6 . Patient present cardiogenic shock . 7 . Any significant medical condition Investigator 's opinion may interfere patient 's optimal participation study . 8 . Currently participate another investigational drug device study . 9 . Unprotected leave main disease . 10 . Ostial target lesion . 11 . Chronic total occlusion . 12 . Calcified target lesion adequately predilated . 13 . Target lesion excessive tortuosity unsuitable stent delivery deployment . 14 . Target lesion involve bifurcation side branch large 2.0mm diameter . 15 . A &gt; 30 % stenosis proximal distal target lesion cover stent . 16 . Diffuse distal disease . 17 . Prior stent target vessel .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Vascular heal coronary stent patient acute coronary syndrome</keyword>
</DOC>